Vena et al. described eczema-like reactions to irbesartan, suggesting that these reactions were related to interference with the kallikrein-kinin system and elevation of circulating and cutaneous pro-inflammatory bradykinin peptides, as ARBs can increase bradykinin levels in hypertensive patients (Campbell et al., 2005; Vena et al., 2013). The gene discussed is KNG1; the disease is Eczematoid dermatitis.